2023 ARRS ANNUAL MEETING - ABSTRACTS

RETURN TO ABSTRACT LISTING


E2016. Magnetic Resonance Imaging Features of Benign Cartilage Tumors: Correlation with Radiographic Findings
Authors
  1. Shannon Yoo; UCLA Health
  2. Fadi Nemeh; UCLA Health
  3. Varand Ghazikhanian; UCLA Health
  4. Kambiz Motamedi; UCLA Health
Background
Benign cartilage bone tumors are the most commonly encountered primary benign bone tumors. As magnetic resonance imaging (MRI) continues to become widely adopted and utilized, radiologists are increasingly encountering incidental cartilage bone tumors that need to be further described and characterized.

Educational Goals / Teaching Points
This educational exhibit will provide an overview of characteristic MRI features with radiographic correlation to accurately narrow down the differential diagnosis among a wide spectrum of benign cartilage bone tumors.

Key Anatomic/Physiologic Issues and Imaging Findings/Techniques
This exhibit will review MRI and radiographic features of osteochondroma, enchondroma, juxtacortical chondroma, chondroblastoma, bizarre parosteal osteochondromatous proliferation, and chondromyxoid fibroma. For each of the benign cartilage tumors presented, additional distinguishing features including the common anatomic location, location within the bone, and clinical presentation will be emphasized. Additionally, appropriate follow-up or treatment options will be reviewed. Lastly, specific imaging features that raise suspicion for malignant degeneration will be described.

Conclusion
Benign cartilage bone tumors are commonly encountered as incidental findings. This educational exhibit will familiarize learners with the typical MRI features of benign cartilage bone tumors, assisted by the radiographic correlation. This educational exhibit will also emphasize imaging features that raise suspicion for malignant degeneration. In an era of increased reliance on MRI, this knowledge should be a part of every radiologist's skillset to allow for an accurate diagnosis of different cartilage bone tumors and to help decrease unnecessary follow-up studies or biopsies.